Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many claims are not supported by the provided FDA label excerpts (e.g., pricing/patent/generics/discounts, analogies about mimicking pituitary hormones, specific adverse reaction symptoms beyond label excerpts). Several safety claims (OHSS, multi-fetal gestation, injection-site reactions/headache/nausea/abdominal pain/bloating) are not clearly supported by the provided label text.
Category Scores
Accurate Statements
Menopur is a gonadotropin medication containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
Supported by Drug/Active ingredient(s): menotropins containing FSH and LH activity (label excerpt: 'Active ingredient(s): menotropins (contains FSH and LH activity').
Menopur can cause ovarian hyperstimulation syndrome (OHSS).
Supported: Warnings and Precautions (5.2) and Adverse Reactions sections mention OHSS.
Menopur can increase the possibility of multiple pregnancies.
Supported: Warnings and Precautions (5.5) reports multiple pregnancy with MENOPUR and advises about potential risk.
Other fertility medications available include other forms of FSH such as Gonal-f, Follistim, and Bravelle.
Partially supported only by mention that MENOPUR may be administered together with BRAVELLE (urofollitropin) (Dosage and Administration 2.1). No support for Gonal-f/Follistim/Ovidrel/Novarel specifically in the provided excerpts.
Unsupported Statements
Menopur is prescribed to stimulate egg development in women undergoing fertility treatments such as in vitro fertilization (IVF) or artificial insemination.
The provided label excerpt does not explicitly state IVF/artificial insemination indication language; it only provides IVF dosing (2.2) and pre-treatment evaluation. No 'artificial insemination' mention in supplied excerpts.
The FSH and LH in Menopur mimic natural hormones produced by the pituitary gland to prepare the ovaries for ovulation.
The supplied label excerpts do not describe a 'mimic pituitary hormones' mechanism.
The cost of Menopur can vary significantly.
Pricing/cost statements are not addressed in the provided label excerpts.
Factors influencing Menopur price include dosage, the number of units required for a treatment cycle, and the pharmacy or healthcare provider dispensing the medication.
No pricing determinants are provided in the provided label excerpts.
A typical Menopur treatment cycle can involve multiple vials.
No vial-count or cycle-vial expectations are given in the provided label excerpts.
Costs for a Menopur treatment cycle can range from several hundred to a few thousand dollars.
No cost range information is present in the provided label excerpts.
A single 600 IU vial of Menopur can cost upwards of $150.
No vial strength of 600 IU is provided in the excerpts; no pricing information is present in the provided label excerpts.
A full Menopur treatment regimen might require several 600 IU vials, along with other medications and procedures.
No 600 IU vial strength is provided in the excerpts; no regimen vial counts or cost-related regimen description is in the provided label excerpts.
Coverage for Menopur varies by insurance plan.
Insurance coverage/payment policy details are not addressed in the provided label excerpts.
Some insurance plans may offer partial or full coverage for fertility treatments, including Menopur.
No insurance coverage details are present in the provided label excerpts.
Some insurance plans may exclude Menopur.
No insurance coverage details are present in the provided label excerpts.
Patients may verify their specific insurance benefits and discuss potential Menopur coverage with their provider and pharmacy.
Label excerpts provided contain no reimbursement/benefits guidance.
Patients may explore patient assistance programs offered by the manufacturer to reduce the cost of Menopur.
No manufacturer assistance program information is provided in the provided label excerpts.
Patients may use discount cards and coupons available through various pharmacies and online platforms to reduce the cost of Menopur.
No coupon/discount card information is present in the provided label excerpts.
Comparing prices across different pharmacies can help find a more affordable option for Menopur.
No pharmacy price comparison advice is present in the provided label excerpts.
Menopur patent expiry information is available through resources like DrugPatentWatch.com.
Patent information sourcing and external websites are not addressed in the provided label excerpts.
Patents protect a drug from generic competition.
General patent/generic explanation is not addressed in the provided label excerpts.
Patent expiry can lead to the introduction of lower-cost generic versions.
No generic/patent policy statements are present in the provided label excerpts.
Menopur can cause injection site reactions, including pain, redness, and swelling.
The provided label excerpts mention abnormal ovarian enlargement, OHSS, pelvic pain, ovarian cyst, breast complaints; they do not specify injection-site pain/redness/swelling.
Menopur can cause headache.
Headache is not mentioned in the provided label excerpts.
Menopur can cause nausea.
Nausea is not mentioned in the provided label excerpts.
Menopur can cause abdominal pain.
Abdominal pain is not mentioned in the provided label excerpts.
Menopur can cause bloating.
Bloating is not mentioned in the provided label excerpts.
Other fertility medications available include ovulation-triggering medications such as Ovidrel and Novarel.
The provided label excerpts mention hCG timing and hCG administration decisions, but do not name Ovidrel or Novarel.
The choice of fertility medication depends on the individual patient's needs and the specific treatment protocol prescribed by their doctor.
While the label excerpt says dosing is individualized (2.2), the general 'choice of medication' statement is not explicitly stated in the provided excerpts.
Contradictions
Important Omissions
Pre-treatment requirements: complete gynecologic/endocrinologic evaluation; exclude pregnancy; evaluate male partner fertility; exclude primary ovarian failure (Section 1).
Importance:
Moderate
Key dosing safety details for IVF/ART: individualized stepwise dosing; starting dose after GnRH agonist suppression; maximum daily and combined dose limits; withhold hCG if increased OHSS risk; therapy should not exceed 20 days (Section 2.2).
Importance:
Moderate
Monitoring recommendations to minimize OHSS/multiple gestation risk (ultrasound and/or serum estradiol; assess for at least two weeks after hCG) (Sections 5.1/5.2/5.10).
Importance:
Moderate
Contraindication in pregnancy and counseling about fetal harm (Section 4; Pregnancy Category X/teratogenic effects).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant adverse reaction claims (headache, nausea, abdominal pain, bloating, injection-site reactions) are not supported by the provided label excerpts, and key label safety information (pre-treatment evaluation, monitoring, exact dosing limits, and pregnancy contraindication) is omitted. While OHSS and multiple pregnancy risks were correctly identified, unsupported and omitted safety details could mislead users about expected adverse effects and safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Many non-label claims (pricing/insurance/patents/discounts) and multiple adverse reaction and mechanism statements are unsupported by the provided prescribing information excerpts; key on-label safety and monitoring content is omitted.
Suggested Improvement
Limit claims to what is present in the MENOPUR label excerpts (e.g., menotropins contain FSH/LH activity; IVF dosing framework; withhold hCG when OHSS risk is increased; monitoring and OHSS/multi-fetal risks; contraindication in pregnancy). Remove or qualify unsupported external topics (pricing, patent sites, coupons) and unsupported adverse reaction symptom lists not present in the provided label text.